Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Medical (NASDAQ: RCEL) said interim CEO Cary Vance and CFO David O’Toole will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 at 8:10 a.m. PT / 11:10 a.m. ET.
A live and archived webcast will be available via the company’s Events & Presentations page at its investor website.
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on Feb 18, 2026 at 2:00 PM PST (Feb 19, 2026 at 9:00 AM AEDT).
Interim CEO Cary Vance and CFO David O’Toole will review fourth-quarter and full-year 2025 financial and business results, followed by a Q&A. A replay will be posted on the company investor site.
AVITA Medical (NASDAQ: RCEL) reported Q4 2025 revenue of $17.6M and full-year revenue of $71.6M (+11% YoY). Q4 net loss was $11.6M (loss of $0.38/share); FY net loss was $48.6M (loss of $1.74/share). Gross margin was 82.1% for the year and cash plus marketable securities ended Q4 at $18.2M. The company closed a five-year credit facility providing up to $60M (initial $50M funded). 2026 revenue guidance: $80–85M.
Management highlighted improved cash efficiency, stabilization of reimbursement after MAC actions, ongoing clinical study enrollment, and execution-focused priorities for 2026.
AVITA Medical (NASDAQ: RCEL) presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, including the first surgeon-reported integrated use of RECELL, PermeaDerm, and Cohealyx in single care pathways.
Initial histological findings from PermeaDerm and Cohealyx trials showed early blood vessel growth and organized tissue formation without increased inflammation. RECELL evidence across comparative studies and registries indicated smaller donor sites, similar or faster healing, fewer complications, and substantial hospital-stay reductions (nearly 16 days shorter in one older-patient study; ~33% less time in hospital in another registry analysis).
AVITA Medical (NASDAQ: RCEL) reported preliminary results and a 2026 outlook ahead of its J.P. Morgan presentation on Jan 14, 2026 at 5:15 p.m. PT. Q4 2025 revenue ~ $17.6M vs $18.4M a year earlier; FY 2025 revenue ~ $71.6M, up ~11% from $64.3M in 2024. The company secured a new five-year credit facility with Perceptive Advisors for up to $60M (initial $50M funded, $10M accordion available).
AVITA provided 2026 revenue guidance of $80–$85M (≈12%–19% growth) and disclosed TTM revenue covenants of $68.5M for Q1-2026 and $73M for FY2026, implying a required $15.4M revenue in Q1 2026. Clinical updates: Cohealyx-I fully enrolled and PermeaDerm-I >75% enrolled; data expected later in 2026.
AVITA Medical (NASDAQ: RCEL) announced board changes on January 5, 2026: Joe Woody was appointed as a non-executive director and Lou Panaccio retired after serving as Chairman from July 2014 to August 2025. The company is led by Interim CEO Cary Vance.
Mr. Woody brings more than two decades of medical-technology leadership, including serving as CEO of Avanos Medical from 2017 to 2024, prior service as President and CEO of Acelity, and over a decade on the AdvaMed board.
AVITA Medical (NASDAQ: RCEL) announced that CEO Cary Vance will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. PT.
A live audio webcast will be available via the company's Investor Relations Events & Presentations page and a replay will be posted after the presentation.
AVITA Medical (NASDAQ: RCEL) will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 8:30 a.m. EST. Management will be available for one-on-one investor meetings at the conference for registered attendees.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's investor website at https://ir.avitamedical.com/events-and-presentations, and a replay will be available after the event.
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on November 12, 2025 at 2:00 p.m. PT (November 13, 2025 at 9:00 a.m. AEDT).
Interim CEO Cary Vance and CFO David O’Toole will review financial and business results from the company’s recent Q3 2025 earnings webcast and hold a live Q&A. Shareholders and prospective investors may register to submit questions in advance. A replay will be available on AVITA Medical’s investor website after the presentation.
AVITA Medical (NASDAQ: RCEL) reported Q3 2025 results for the quarter ended September 30, 2025. Commercial revenue was $17.1M, down 13% year-over-year. Operating expenses fell 24% to $23.0M, and net loss improved to $13.2M, or $0.46 per share, from $16.2M a year earlier. Cash, cash equivalents, and marketable securities totaled $23.3M at quarter end after a $13.8M private placement.
Key developments: RECELL GO received CE Mark under the EU MDR enabling launches in Germany, Italy, and the U.K.; real-world data showed a 36% reduction in hospital length-of-stay and approximately $42,000 per-patient cost savings versus split-thickness grafts; full-year 2025 revenue guidance was lowered to $70–$74M. The company amended its credit agreement, adding $500,000 to loan principal and resetting a revenue covenant to $70M for Q4 2025.